Charles Schwab
BCAX

Charles Schwab’s Bicara Therapeutics BCAX Stock Holding History

Charles Schwab’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9M Buy
365,481
+101,496
+38% +$2.27M ﹤0.01% 2118
2026
Q1 		$5.25M Sell
263,985
-8,160
-3% -$140K ﹤0.01% 2381
2025
Q4 		$4.58M Sell
272,145
-8,731
-3% -$149K ﹤0.01% 2495
2025
Q3 		$4.44M Buy
280,876
+87,823
+45% +$983K ﹤0.01% 2495
2025
Q2 		$1.79M Buy
193,053
+40,049
+26% +$477K ﹤0.01% 2699
2025
Q1 		$1.99M Sell
153,004
-3,780
-2% -$50.2K ﹤0.01% 2621
2024
Q4 		$2.73M Buy
+156,784
New +$3.26M ﹤0.01% 2579

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's BCAX Position: Q2 2026 in Review

Charles Schwab increased its Bicara Therapeutics (BCAX) stake by 38% in Q2 2026, buying an estimated $2.27M and bringing the position to 365,481 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2118.

Charles Schwab first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. 170 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Charles Schwab held 365,481 shares of Bicara Therapeutics worth $10.9M as of Q2 2026.
  • Charles Schwab bought 101,496 Bicara Therapeutics shares in Q2 2026, an estimated $2.27M.
  • Bicara Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2118 holding.
  • Charles Schwab first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 170 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.